• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott Laboratories

Famed marathoner uses Abbott glucose sensor for training

April 12, 2021 By Brian Buntz

Abbott logo updated

Kenyan long-distance runner Eliud Kipchoge is using a glucose sensor modeled after Abbott Laboratories’ FreeStyle Libre glucose monitor to optimize his training regimen.  The sensor, known as the Libre Sense Glucose Sport Biosensor, is the first device intended to help athletes track blood sugar rather than people with diabetes.  Kipchoge, who set a world record […]

Filed Under: Diabetes Tagged With: Abbott Laboratories, Abbott Libre Sense, CGM, continuous glucose monitor, Diabetes, glucose sensor

Abbott’s FreeStyle Libre 3 receives CE Mark

September 28, 2020 By Chris Newmarker

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) has won the CE Mark in the European Union for its next-generation FreeStyle Libre 3 continuous glucose monitoring system. Officials at Abbott boast that the Libre 3 technology includes a super small, thin sensor. It’s the size of two U.S. pennies stacked together and able to accurately provide real-time glucose readings over 14 days […]

Filed Under: Business/Financial News, Diabetes, Diagnostics, Featured, Regulatory/Compliance Tagged With: abbott, Abbott Laboratories

Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes

July 9, 2020 By Chris Newmarker

Medtronic Tandem Diabetes Care

Two major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) — announced today that they’ve inked a non-exclusive patent cross-license agreement related to diabetes treatment tech. The companies said the agreement will allow them to focus on innovation while avoiding the distraction of potential legal disagreements. The deal could be but another example of […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News Tagged With: Abbott Laboratories, insulin, Tandem Diabetes Care

Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech

January 13, 2020 By Chris Newmarker

Bigfoot Biomedical Abbott Bigfoot Unity diabetes management program Insulet acquires Bigfoot assets

Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT)  as the lead investor. “We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release today.  […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, Abbott Laboratories, artificial pancreas, Bigfoot Biomedical, insulin

Bigfoot Biomedical raises $37m in Series B

December 18, 2017 By Sarah Faulkner

Bigfoot Biomedical

Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Abbott Laboratories, Bigfoot Biomedical

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds

October 12, 2017 By Sarah Faulkner

Abbott

Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Boston Scientific, Elixir Medical Corporation, Reva Medical

Bigfoot Biomedical taps Abbott to collaborate on automated insulin delivery tech

July 13, 2017 By Sarah Faulkner

Bigfoot Biomedical

Abbott (NYSE:ABT) and Bigfoot Biomedical said today that the companies inked a deal to develop and commercialize diabetes management systems. The collaboration will bring together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform, the companies reported. According to the deal, Abbott will provide Bigfoot with the next-gen version of its FreeStyle Libre continuous […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Abbott Laboratories, Bigfoot Biomedical

Amaranth Medical looks to recapture the potential of bioresorbable scaffolds

June 7, 2017 By Sarah Faulkner

Amaranth Medical

Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]

Filed Under: Drug-Device Combinations, Featured, Stents, Vascular Tagged With: Abbott Laboratories, amaranthmedical

EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard

May 22, 2017 By Sarah Faulkner

Updated to include a statement from an Abbott spokesperson.  Abbott‘s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott restricted use of the Absorb devices to clinical registry studies. In response […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Abbott Laboratories, amaranthmedical, Medtronic, Micell Technologies, Reva Medical, sveltemedicalsystem, xience

Sanofi promotes Sibold to exec VP of Sanofi Genzyme | Personnel Moves – April 13, 2017

April 17, 2017 By Sarah Faulkner

Sanofi logo

Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]

Pages: Page 1 Page 2

Filed Under: Drug-Device Combinations, Featured, Personnel, Wall Street Beat Tagged With: Abbott Laboratories, bausch&lomb, Biogen Idec, Bristol-Myers Squibb Co., Gerresheimer AG, GlucoMe, Mylan, Ocular Therapeutix, Pulmatrix Inc., Sanofi-Aventis

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS